test

John D Roberts MD

Professor of Medicine (Medical Oncology); Medical Director, Adult Sickle Cell Program at Yale-New Haven Hospital

Clinical Interests

sickle cell disease; medical oncology phase I trials; urological cancers (prostate, bladder, testicle)


Board Certifications

2012
Hospice & Palliative Medicine, Board Certified
1980
Internal Medicine, Board Certified
1985
Medical Oncology, Board Certified

Patient Care Locations

john_d_robertsfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
BladderGO29293: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER
ProstatePhase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy
Breast - Female, Colon, Esophagus, Lung, and Melanoma, skin(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 8 ┬┐ LEE011 for patients with CDK4/6 pathway activated tumors
Bladder, Breast - Female, Breast - Male, Colon, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Skin, Other Urinary, Pancreas, Prostate, Small Intestine, and StomachA Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects with Advanced Tumors
Unknown SitesModular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors

More Clinical Trials...

Edit Profile